HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- (2- carboxypiperazin- 4- yl)propyl- 1- phosphonic acid

structure given in first source; NMDA receptor antagonist

Also Known As:

3-2-CPP; 4-(3-phosphonopropyl)-2-piperazinecarboxylic acid

Networked: 9 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperazines: 26
    - 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid: 9

Experts

1.	Delivoria-Papadopoulos, M: 1 article (02/2001)
2.	Fritz, K I: 1 article (02/2001)
3.	Mishra, O P: 1 article (02/2001)
4.	Zanelli, S: 1 article (02/2001)

Related Diseases

1.	Wounds and Injuries (Trauma) 05/19/1989 - "Treatment with the noncompetitive N-methyl-D-aspartate (NMDA) antagonist dextrophan or the competitive antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid limited the resultant neurological dysfunction; dextrorphan treatment also improved the bioenergetic state after trauma and increased the intracellular free magnesium. " 01/10/1990 - "The potential role of N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of spinal cord injury was examined in rats by comparing the effects of the non-competitive NMDA antagonist dextrorphan and the competitive NMDA antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) on the behavioral and anatomical consequences of impact trauma to the spinal cord. "
2.	Hypoxia (Hypoxemia) 02/09/2001 - "The present study tests the hypothesis that the NMDA receptor 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) high-affinity binding site is modified during hypoxia and that the degree of modification correlates with the progressive decrease in cerebral cellular energy metabolism and increase in lipid peroxidation induced by hypoxia. " 08/05/1996 - "The present study tests the hypothesis that blockade of the glutamate recognition site of the NMDA receptor with the competitive antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) prevents modification of the receptor during hypoxia. "
3.	Spinal Cord Injuries (Spinal Cord Injury) 01/01/1998 - "We observed the effects of Glu and dynorphin DynA1-13 administered intrathecally on function of spinal cord in rats and the effects of 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), an antagonist of EAA receptor, and antisera against dynorphin administered intrathecally on secondary spinal cord injury. " 01/10/1990 - "The potential role of N-methyl-D-aspartate (NMDA) receptors in the pathophysiology of spinal cord injury was examined in rats by comparing the effects of the non-competitive NMDA antagonist dextrorphan and the competitive NMDA antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) on the behavioral and anatomical consequences of impact trauma to the spinal cord. "
4.	Pain (Aches) 11/01/1992 - "This case report describes the use of an NMDA receptor antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP) in a carefully selected patient with severe and intractable neurogenic pain in her left leg. " 05/01/1994 - "The N-methyl-D-aspartate (NMDA) receptor antagonist 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP), which produces antinociception in experimental animal models after spinal administration, may be of value in clinical pain treatment. "
5.	Hyperkinesis 12/01/1989 - "To test the hypothesis that the motor hyperactivity associated with intra-accumbens injections of N-methyl-d-aspartate (NMDA) results from stimulation (direct or indirect) of nucleus accumbens dopaminergic mechanisms, the behavioral effects of intra-accumbens and intraventricular NMDA were compared to those of the prototypic dopaminergic releasing agent, amphetamine, and the competitive NMDA receptor antagonist, 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP). "

Related Drugs and Biologics

1.	N-Methylaspartate (NMDA)
2.	Dextrorphan
3.	Magnesium
4.	6-chloro-2-(1-piperazinyl)pyrazine (CPP)
5.	N-Methyl-D-Aspartate Receptors (NMDA Receptors)
6.	Glutamic Acid (Glutamate)
7.	Glutamate Receptors (Glutamate Receptor)
8.	Immune Sera (Antisera)
9.	Dynorphins (Dynorphin)
10.	Amphetamine (Amfetamine)

Related Therapies and Procedures

1.	Injections
2.	Aftercare (After-Treatment)